Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19.
作者信息
Gautret Philippe, Lagier Jean-Christophe, Honoré Stéphane, Hoang Van Thuan, Raoult Didier
机构信息
IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.
IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.
出版信息
Int J Antimicrob Agents. 2021 Jan;57(1):106242. doi: 10.1016/j.ijantimicag.2020.106242.
Abstract
摘要
相似文献
1
Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19.
Int J Antimicrob Agents. 2021 Jan;57(1):106242. doi: 10.1016/j.ijantimicag.2020.106242.
2
Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients.
Int J Antimicrob Agents. 2021 Jan;57(1):106236. doi: 10.1016/j.ijantimicag.2020.106236.
3
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited.
Int J Antimicrob Agents. 2021 Jan;57(1):106243. doi: 10.1016/j.ijantimicag.2020.106243.
4
Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.
Int J Antimicrob Agents. 2021 Jan;57(1):106240. doi: 10.1016/j.ijantimicag.2020.106240.
5
Interpretation of SARS-CoV-2 PCR results for the diagnosis of COVID-19.
Int J Antimicrob Agents. 2021 Jan;57(1):106238. doi: 10.1016/j.ijantimicag.2020.106238.
6
Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes.
Int J Antimicrob Agents. 2021 Jan;57(1):106239. doi: 10.1016/j.ijantimicag.2020.106239.
7
Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.
Int J Antimicrob Agents. 2021 Jan;57(1):106172. doi: 10.1016/j.ijantimicag.2020.106172.
8
Advanced statistical methods and designs for clinical trials for COVID-19.
Int J Antimicrob Agents. 2021 Jan;57(1):106167. doi: 10.1016/j.ijantimicag.2020.106167.
9
Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.
Int J Antimicrob Agents. 2021 Jan;57(1):106174. doi: 10.1016/j.ijantimicag.2020.106174.
10
Uncertain effects of hydroxychloroquine and azithromycin on SARS-Cov-2 viral load.
Int J Antimicrob Agents. 2021 Jan;57(1):106169. doi: 10.1016/j.ijantimicag.2020.106169.
引用本文的文献
1
Importance of Magnesium Status in COVID-19.
Biology (Basel). 2023 May 18;12(5):735. doi: 10.3390/biology12050735.
2
Identification of Drug Interaction Adverse Events in Patients With COVID-19: A Systematic Review.
JAMA Netw Open. 2022 Apr 1;5(4):e227970. doi: 10.1001/jamanetworkopen.2022.7970.
3
COVID-19 Prophylaxis Efforts Based on Natural Antiviral Plant Extracts and Their Compounds.
Molecules. 2021 Jan 30;26(3):727. doi: 10.3390/molecules26030727.
本文引用的文献
1
Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".
Int J Antimicrob Agents. 2021 Jan;57(1):106175. doi: 10.1016/j.ijantimicag.2020.106175.
2
Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis.
Travel Med Infect Dis. 2020 Jul-Aug;36:101791. doi: 10.1016/j.tmaid.2020.101791. Epub 2020 Jun 25.
Zotero 插件